HIMS is trading about 5% down today at $31.07 as the stock gives back gains from a recent rebound amid persistent GLP-1 supply uncertainty and valuation concerns.
- The decline follows a sharp recovery from earlier 2026 lows, with the stock still down over 50% year-to-date due to regulatory and litigation headwinds.
- Market sentiment remains cautious regarding prior FDA actions and the long-term outlook for weight-loss drug availability.
- No fresh company-specific headlines were released today, suggesting the price action is driven by existing macro and sector-specific overhangs.